{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:47:27Z","timestamp":1787950047950,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113474","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:59:16Z","timestamp":1730289556000},"page":"113474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"P2","title":["Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study"],"prefix":"10.1016","volume":"143","author":[{"given":"Zheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanglei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2024.113474_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113474_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jdv.16202","article-title":"Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response","volume":"34","author":"Rompoti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/jdv.15288","article-title":"Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study","volume":"33","author":"Deza","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113474_b0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ad.2019.02.006","article-title":"Efficacy and Safety of Ixekizumab in a Real-Life Practice: A Retrospective Bicentric Study","volume":"110","author":"Magdaleno-Tapial","year":"2019","journal-title":"Actas Dermosifiliogr (engl Ed)."},{"issue":"9","key":"10.1016\/j.intimp.2024.113474_b0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/ced.15237","article-title":"Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Exp Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113474_b0040","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s13555-023-00969-1","article-title":"Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program","volume":"13","author":"Gottlieb","year":"2023","journal-title":"Dermatol Ther (heidelb)."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jaad.2018.03.008","article-title":"Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113474_b0050","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1111\/jocd.15217","article-title":"Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting","volume":"21","author":"Demirel \u00d6\u011f\u00fct","year":"2022","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.intimp.2024.113474_b0055","doi-asserted-by":"crossref","first-page":"1185523","DOI":"10.3389\/fmed.2023.1185523","article-title":"Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"10","author":"Piaserico","year":"2023","journal-title":"Front Med (lausanne)."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0060","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","article-title":"Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis","volume":"33","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0065","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0070","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113474_b0075","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/09546634.2021.1961998","article-title":"Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study","volume":"33","author":"Dapavo","year":"2022","journal-title":"J Dermatolog Treat."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years","volume":"38","author":"Mastorino","year":"2024","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113474_b0085","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2023.2193288","article-title":"Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study","volume":"23","author":"Caldarola","year":"2023","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.intimp.2024.113474_b0090","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2147\/CCID.S387759","article-title":"Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study","volume":"15","author":"Li","year":"2022","journal-title":"Clin Cosmet Investig Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113474_b0095","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113474_b0100","doi-asserted-by":"crossref","first-page":"e14808","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0105","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0110","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/1346-8138.16737","article-title":"Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study","volume":"50","author":"Yanase","year":"2023","journal-title":"J Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113474_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1346-8138.15146","article-title":"Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan","volume":"47","author":"Kishimoto","year":"2020","journal-title":"J Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113474_b0120","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113474_b0125","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/CM9.0000000000002130","article-title":"Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin Med J (engl)."},{"issue":"1","key":"10.1016\/j.intimp.2024.113474_b0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0135","first-page":"535","article-title":"Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters","volume":"11","author":"Piros","year":"2021","journal-title":"Life (basel)."},{"issue":"18","key":"10.1016\/j.intimp.2024.113474_b0140","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3678","article-title":"Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis","volume":"100","author":"Phan","year":"2020","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0145","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1111\/jdv.16063","article-title":"Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period","volume":"34","author":"Megna","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113474_b0150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","article-title":"Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)","volume":"44","author":"Saeki","year":"2017","journal-title":"J Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113474_b0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis","volume":"160","author":"Al-Janabi","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113474_b0160","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jaad.2020.06.012","article-title":"No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis","volume":"83","author":"Mrowietz","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113474_b0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational","volume":"25","author":"Torres","year":"2024","journal-title":"Multicentre Study. Am J Clin Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113474_b0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2018.11.016","article-title":"An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis","volume":"5","author":"Koike","year":"2019","journal-title":"JAAD Case Rep."},{"issue":"3","key":"10.1016\/j.intimp.2024.113474_b0175","doi-asserted-by":"crossref","first-page":"e12909","DOI":"10.1111\/dth.12909","article-title":"Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection","volume":"32","author":"Lora","year":"2019","journal-title":"Dermatol Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0180","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/1346-8138.16320","article-title":"Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate","volume":"49","author":"Kishimoto","year":"2022","journal-title":"J Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113474_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40800-017-0051-2","article-title":"Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient","volume":"4","author":"Chu","year":"2017","journal-title":"Drug Saf Case Rep."},{"issue":"12","key":"10.1016\/j.intimp.2024.113474_b0190","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1111\/jdv.15775","article-title":"A real-life experience of psoriatic patients with history of cancer treated with biological drugs","volume":"33","author":"Odorici","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113474_b0195","doi-asserted-by":"crossref","DOI":"10.5070\/D327654071","article-title":"Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies","volume":"27","author":"Porcar Saura","year":"2021","journal-title":"Dermatol Online J."},{"issue":"4","key":"10.1016\/j.intimp.2024.113474_b0200","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1684\/ejd.2021.4087","article-title":"Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient","volume":"31","author":"Vinaixa Aranzazu","year":"2021","journal-title":"Eur J Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113474_b0205","doi-asserted-by":"crossref","first-page":"e14889","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:33:55Z","timestamp":1736303635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924019969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"alternative-id":["S1567576924019969"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113474","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113474"}}